Back to search results

A Study of INCA036873 for Advanced Solid Tumors and Blood Cancers

This study is testing a new treatment called INCA036873, which is a CAR T-cell therapy, for people with advanced solid tumors and blood cancers (hematological malignancies). The main goal is to see how safe INCA036873 is and what side effects it might cause. Researchers will look for serious side effects within the first 28 days and track all side effects for up to two years and 90 days. You may be able to join if you are 18 or older, have a good performance status (ECOG 0 or 1), and have specific types of kidney cancer (clear cell renal cell carcinoma) or lymphoma (diffuse large B-cell lymphoma, high-grade B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma). The study aims to enroll 280 participants, but its current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 280 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for treatment-emergent adverse events for up to approximately 2 years and 90 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07195916

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Recruiting
PHASE1Ages 18+InterventionalTreatment
Incyte Corporation
~280 participants
Updated 2026-09-15 on ClinicalTrials.gov
What's tested:INCA036873

At a glance

Recruiting sites
16 of 22 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)
Measured over Up to Day 28
+1 more outcome measured

Conditions

Solid Tumors
Hematologic Malignancies

Explore related trials

Clear Cell Renal Cell CarcinomaDiffuse Large B-Cell LymphomaHematologic NeoplasmHigh Grade B-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaPrimary Cutaneous T-Cell Non-Hodgkin LymphomaSolid Neoplasm

NCT07195916

Where you'd take part

This study runs at 22 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Aarhus University Hospital

    Aarhus, Denmarkno site contact published

    Not yet recruiting

  • Aou Policlinico S. Orsola-Malpighi

    Bologna, Italyno site contact published

    Not yet recruiting

  • Cancer Research Sa

    Adelaide, South Australia, Australiano site contact published

    Recruiting

  • Centro Ricerche Cliniche Di Verona

    Verona, Italyno site contact published

    Not yet recruiting

  • City of Hope Medical Center

    Duarte, Californiano site contact published

    Recruiting

  • Cliniques Universitaires Ucl Saint-Luc

    Brussels, Belgiumno site contact published

    Recruiting

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan, Italyno site contact published

    Not yet recruiting

  • Macquarie University Hospital

    Sydney, New South Wales, Australiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Incyte Study Monitor · STUDY_DIRECTOR · Incyte Corporation

Who to contact

Incyte Corporation Call Center (US)
[email protected]
1.855.463.3463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
ECOG performance status of 0 or 1.
Histologically confirmed:
Clear cell renal cell carcinoma (ccRCC).
Diffuse large B-cell lymphoma (DLBCL, NOS).
High-grade B-cell lymphoma (HGBCL).
Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
Disease progression, relapse, or refractory to prior therapy:
ccRCC: ≥1 prior line incl. ICI + TKI.
DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
PTCL/CTCL: ≥1 prior systemic therapy.
Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
Tumor tissue available for central testing.

Exclusion

Untreated or progressive CNS disease unless previously treated and stable.
Other active invasive malignancy within 2 years (except certain low-risk cancers).
Prior CD70-targeting therapy, including CAR T.
ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
Pregnancy, breastfeeding, or unwillingness to use effective contraception.

What this trial measures

  • Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)Up to Day 28

    Toxicities occurring during the first study drug infusion and continues through 28 days as defined in the protocol. DLTs will be assessed for severity by the investigator using CTCAE v5.0 criteria.

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs)Up to approximately 2 years and 90 days

    TEAE is any Adverse Event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.